Researchers at King's College London have developed a novel do-it-yourself blood testing device, named Algocyte, which could significantly streamline the diagnostic process and enable earlier detection of various health conditions. The device requires only a finger-prick of blood to provide results within five to 25 minutes via a smartphone application. Scientists hope this technology could be integrated into the UK's National Health Service (NHS) and potentially revolutionize home-based health monitoring.
How Algocyte Works
The unassuming white box, weighing less than 2kg, operates with a simple lancet to draw a small blood sample. This sample is then placed into a cartridge that slots into the machine. Two separate readings are performed to analyze different blood cell types, a process that takes approximately 10 minutes. Within 25 minutes, the results are transmitted to a paired smartphone app, presenting an easily understandable report of the measurements.
Dr. Hector Zenil, the founder of Algocyte and an Associate Professor in Healthcare Engineering at King's College London, stated that if used within the NHS, results would first be sent to the patient's clinician. He highlighted that Algocyte analyzes 11 key blood markers, a number significantly higher than its two known competitors, which can only analyze three or four details. These markers are crucial for identifying abnormalities linked to conditions such as cancer and infections, as well as deficiencies like anemia.
Potential Applications and Future
The device has already obtained a UKCA mark, signifying its compliance with British health, safety, and environmental standards. Discussions are underway with Oxford University Hospitals, as well as care homes and an eye clinic, to explore potential uses. In the future, Dr. Zenil envisions Algocyte being available for private purchase by individuals for around £1,000, allowing for continuous health monitoring at home.
Dr. Zenil suggested that Algocyte aligns with the NHS's strategy of keeping patients at home through initiatives like virtual wards and community hubs, offering a way to monitor individuals and reduce costly emergency events such as sepsis. The app also has the capability to track changes over time, creating a personalized health profile and flagging potentially worrying trends before diseases develop. Future iterations could potentially monitor liver toxicity, which Dr. Zenil indicated would be particularly beneficial for cancer patients.
While current paid-for DIY blood tests often involve significant delays due to lab analysis, Algocyte offers rapid results. However, it is important to note that clinical blood tests performed in hospitals are more comprehensive, analyzing 50 or more markers. Dr. Zenil positions Algocyte as a tool for ongoing monitoring of diagnosed conditions or flagging declines in health, enabling individuals to make lifestyle changes or seek medical attention proactively. He emphasized that the current healthcare system is largely reactive, with treatments designed for when illness is already present, whereas Algocyte could support a shift towards prevention.
